文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Feasibility and acceptability of wearing a neuromodulation device at night in individuals in recovery from opioid use disorder.

作者信息

Meads Kristy L, Huettner Steve, Amata Dexter, Johnson Hailey, Devine Jaime K, Warnakulasuriya Shenali, Murphy Keith R, Good Cameron H

机构信息

Attune Neurosciences, Bel Air, MD, United States.

Stevenson University, Owings Mills, MD, United States.

出版信息

Front Psychiatry. 2024 Nov 29;15:1481795. doi: 10.3389/fpsyt.2024.1481795. eCollection 2024.


DOI:10.3389/fpsyt.2024.1481795
PMID:39676914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11640868/
Abstract

INTRODUCTION: Opioid use disorder (OUD) is a serious and persistent problem in the United States with limited non-pharmacological treatment options, especially for the concomitant sleep disorders experienced by most individuals with addiction. While new, non-invasive interventions such as low-intensity focused ultrasound (LIFU) have shown promise in targeting the brain regions impacted throughout addiction and recovery, the devices used are not amenable to outpatient treatment in their current form factor and cannot be used at night during sleep. To bridge this gap and provide a much-needed treatment option for repeated, at-home use, we developed a wearable LIFU device out-of-clinic use. METHODS: This study evaluated the feasibility and acceptability of the portable treatment device among individuals recovering from OUD in an unsupervised, at-home setting. 31 subjects were recruited from a Baltimore, Maryland (USA) outpatient treatment facility and, along with a separate group of 14 healthy controls (HC), were asked to wear a prototype EEG-only (non-LIFU) device for 7 consecutive nights to assess their willingness and adherence to nightly use. Participants used a smartphone application, TrialKit (ePRO), to self-report nightly sleep data (e.g. duration, quality, possible disturbances, and device comfort). RESULTS: Of the 31 OUD participants recruited, 30 (97%) successfully completed the at-home study, and the majority responded that they would participate in future studies using the head wearable device (OUD, 87%; HC, 71%). OUD participants were statistically more likely than HCs to respond that they would consider using the device in the future to help them sleep (OUD, 70%; HC, 29%). Despite some participants facing technological issues (e.g. lack of reliable phone access or cellular data plans), the OUD group demonstrated high study compliance on par with the healthy control group. DISCUSSION: Participant's daily ePRO and exit interview results established that at-home use of advanced treatment technology is feasible in a population group challenged with recovering from OUD. Even more so, numerous participants noted strong willingness to participate in future LIFU-enabled intervention studies to address their persistent sleep issues during recovery.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/631ece205af9/fpsyt-15-1481795-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/c757b0fa4792/fpsyt-15-1481795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/7d3e9090a7b9/fpsyt-15-1481795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/631ece205af9/fpsyt-15-1481795-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/c757b0fa4792/fpsyt-15-1481795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/7d3e9090a7b9/fpsyt-15-1481795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31fe/11640868/631ece205af9/fpsyt-15-1481795-g003.jpg

相似文献

[1]
Feasibility and acceptability of wearing a neuromodulation device at night in individuals in recovery from opioid use disorder.

Front Psychiatry. 2024-11-29

[2]
Rest-Activity Rhythms, Their Modulators, and Brain-Clinical Correlates in Opioid Use Disorder.

JAMA Netw Open. 2025-2-3

[3]
Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.

JMIR Res Protoc. 2024-6-6

[4]
Feasibility and Acceptability of Wearable Sleep Electroencephalogram Device Use in Adolescents: Observational Study.

JMIR Mhealth Uhealth. 2020-10-1

[5]
Acceptability and Usability of a Wearable Device for Sleep Health Among English- and Spanish-Speaking Patients in a Safety Net Clinic: Qualitative Analysis.

JMIR Form Res. 2023-6-5

[6]
Development and Evaluation of a Digital App for Patient Self-Management of Opioid Use Disorder: Usability, Acceptability, and Utility Study.

JMIR Form Res. 2024-4-1

[7]
A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.

JMIR Res Protoc. 2023-1-20

[8]
Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder.

PLoS One. 2024-6-13

[9]
A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.

Trials. 2021-6-22

[10]
Contextual barriers and enablers to establishing an addiction-focused consultation team for hospitalized adults with opioid use disorder.

Addict Sci Clin Pract. 2024-4-26

引用本文的文献

[1]
Neurotechnology for enhancing human operation of robotic and semi-autonomous systems.

Front Robot AI. 2025-5-23

本文引用的文献

[1]
Thalamic transcranial ultrasound stimulation in treatment resistant depression.

Brain Stimul. 2024

[2]
Non-invasive suppression of the human nucleus accumbens (NAc) with transcranial focused ultrasound (tFUS) modulates the reward network: a pilot study.

Front Hum Neurosci. 2024-4-2

[3]
Transcranial focused ultrasound of the amygdala modulates fear network activation and connectivity.

Brain Stimul. 2024

[4]
Low-intensity focused ultrasound targeting the nucleus accumbens as a potential treatment for substance use disorder: safety and feasibility clinical trial.

Front Psychiatry. 2023-9-15

[5]
Transcranial focused ultrasound-mediated neurochemical and functional connectivity changes in deep cortical regions in humans.

Nat Commun. 2023-9-1

[6]
Low-Intensity Focused Ultrasound Targeting the Bilateral Nucleus Accumbens as a Potential Treatment for Substance Use Disorder: A First-in-Human Report.

Biol Psychiatry. 2023-12-1

[7]
Best Practice Recommendations for Electronic Patient-Reported Outcome Dataset Structure and Standardization to Support Drug Development.

Value Health. 2023-8

[8]
Sleep Medication Use in Adults Aged 18 and Over: United States, 2020.

NCHS Data Brief. 2023-1

[9]
Mobile phone and internet use among people who inject drugs: Implications for mobile health interventions.

Subst Abus. 2022

[10]
Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.

Exp Clin Psychopharmacol. 2022-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索